Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
Geneva, Switzerland, 18 October, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in […]